Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial.
Journal: Pulmonary therapy
Published: May 29, 2026
A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease.
Journal: Pulmonary circulation
Published: October 17, 2025
Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial.
Journal: Respiratory investigation
Published: September 04, 2025
A Phase IIa, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Brensocatib in Adults with Cystic Fibrosis.
Journal: Clinical pharmacokinetics
Published: July 10, 2025
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Journal: The New England journal of medicine
Published: April 23, 2025
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study.
Journal: The Lancet. Respiratory medicine
Published: March 11, 2025
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.
Journal: American journal of respiratory and critical care medicine
Published: February 12, 2025
Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial.
Journal: ERJ open research
Published: February 29, 2024
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.
Journal: ERJ open research
Published: February 15, 2024
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Journal: Respiratory research
Published: February 28, 2023
Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis.
Journal: ERJ open research
Published: December 10, 2022
Impact of exacerbations on lung function, resource utilization, and productivity: results from an observational, prospective study in adults with uncontrolled asthma.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: October 11, 2022
Last Updated: 09/26/2026